Background -Inhaled morphine has previously been shown to increase exercise endurance in patients with chronic lung disease. A similar study was performed to determine whether inhaled morphine reduces the sensation of breathlessness in this group of patients. Methods -A randomised double blind study on the effect of nebulised morphine on both exercise induced breathlessness and maximum achievable power output using isotonic saline as a control was performed in 10 patients with stable chronic lung disease. Each subject performed a progressive exercise test (Jones' stage I) on an electrically braked cycle ergometer. The work load was increased by 10 watts per minute and subjects exercised to exhaustion. At the end of each minute of exercise patients were asked to rate their degree of breathlessness according to a modified Borg scale. All subjects were randomised to receive either inhaled morphine sulphate 1 mg/ml (5 ml) or isotonic saline (5 ml) by wet nebulisation. The effect of morphine and saline on the achieved exercise capacity and the development of breathlessness during exercise was tested on separate days. Results -The mean dose of morphine inhaled was 1-24 mg. There was no difference in maximum power output achieved, minute ventilation at maximum power output, nor the degree of breathlessness at maximum power output between the groups treated with morphine and placebo. The degree ofbreathlessness was related to the power output achieved during exercise by a power function relationship (mean r: morphine = 0'86, saline = 0.87). However, there was a wide variation in the sensation for any given power output in both groups.
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There was no difference in the group mean slopes (morphine = 1l15, saline = 1.00) or intercepts (morphine = 0-07, saline = 0-15) in this relationship between the morphine and saline treatment groups. Breathlessness is a common and distressing symptom of chronic lung disease but, despite maximal treatment, many patients continue to experience persistent and disabling symptoms. In recent years there have been significant advances in our understanding of the nature of this symptom but, despite increases in knowledge, the underlying mechanisms by which the symptom of breathlessness is generated have yet to be elucidated. In an attempt to modify the sensation ofbreathlessness or its perception many drugs including dihydrocodeine,1-3 morphine,"6 and diazepam78 have been tested.
Conclusions
These studies have, however, led to conflicting and inconclusive results.
Young et al6 recently examined the effect of inhaled morphine sulphate on exercise endurance in patients with chronic lung disease and found an increase in endurance in the morphine treated group. This result could be interpreted to show that inhaled morphine relieves breathlessness even though breathlessness per se was not measured. In order to clarify this potential misconception and to determine if small but safe doses of morphine might be associated with relief of breathlessness, we undertook a similar double blind, placebo controlled study with the express aim of determining the effect of modest but safe doses of inhaled morphine sulphate on exercise induced breathlessness in a similar group of patients.
Methods

SUBJECTS
Ten subjects with stable chronic lung diseases recruited from the respiratory outpatient clinic were studied ( The relationship between the Borg score and the power outputs at which they were measured was found to follow a power function relationship in all subjects studied. Intercepts and slopes were calculated for each individual and Borg scores at standard power outputs, selected to lie within the measured range, were determined by interpolation. Group mean results were expressed as the arithmetic mean of the Borg scores at these particular power outputs. Two way analysis ofvariance was used to determine the significance between the study groups. Statistical differences between the measured indices at maximum power output were compared using the Wilcoxon rank sum test.
Results
The characteristics of the 10 patients (six men) are summarised in Power output (Watts)
Effect of saline (0) In studying the effect of low do, morphine on exercise induced brea we adopted a protocol that allowed i imise the number of assessments o lessness (Borg scores practice this often distressing symptom demands relief. The treatment of breathlessness is most effective when the primary cause can be identified and modified but, in those conditions in which treatment currently has little to offer, it is intuitively attractive to attempt to manipulate the symptom of breathlessness itself.
Over the years many attempts have been made in this regard and, although there have been some claims of success, none has achieved more than an alteration ofthe underlying mech-I, anical events which subserve the symptom of 40 50 breathlessness -for example, ventilatory drive, the pattern of breathing, etc. It is our view and has been published elsewhere that claims that lationship these studies show that breathlessness per se output has been reduced cannot be upheld.'2 Opiates have long been popular treatment for the alleviation of breathlessness in patients with respiratory disease. However, they have )1-15, mean not achieved widespread usage largely because l r=0-87). of potential side effects such as respiratory nsation for depression and addiction. There are a number )s (figure); of possible mechanisms by which nebulised )nship was morphine may alleviate the sensation of breathay analysis lessness a short time after inhalation. Firstly, morphine may reduce the degree of anxiety experienced by a particular subject and hence the degree of breathlessness; secondly, perceptual responses to the incoming neural traffic n are com-or its central interpretation may be blunted; Ladvanced and, finally, nebulised morphine may alleviate nts Young the sensation ofbreathlessness a short time after low dose inhalation by direct local action on peripheral rcise en-neural receptors in small airways. Opioid pepLy to deter-tide-like activity has been detected in bronchial duces the mucosa cells'3 and thus morphine may be in a :)ur results position to modify the perception of breathe does not lessness in the same way as it alters the perin patients ception of pain. In our study we believe that and, fur-any anxiety experienced by our subjects was maximum minimal. They were all well known to us having ressive ex-attended our department for some years and had a good understanding of their condition se inhaled and the tests to be performed. The mean inithlessness haled dose of morphine was 1 24 mg in our us to max-study which was comparable to that used by of breath-Young et al6 and was sufficiently low for it to obtained. be unlikely to have caused any central deincreased pression that could have resulted in a reduction )er minute in breathlessness. Furthermore, as the surface ements or area of the small airways is large, there remains )plemental some doubt as to whether a sufficient amount ty the de-of the drug was delivered to achieve any direct ypoxaemia effect on peripheral neural receptors in these lination of airways. It is also possible that the dose of of breath-morphine used in this study was too small to obtained. achieve any direct effect. We used 5 mg of e of seven morphine delivered by wet nebulisation via a )ject, thus jet nebuliser and face mask. New nebulisers lata points were used and the amount of morphine dethese two livered to the airway was calculated from the difference in weights before and after neesensation bulisation multiplied by 0-33 to account for ely under-that volume blown away (assumes that inin detail. " spiration was one third of the respiratory cycle). edge of the Other losses -for example, condensate in the ness, these face mask -are likely to be small and have In clinical been ignored. Future studies using varying con-centrations of nebulised morphine in higher doses to assess breathlessness and exercise endurance are needed to determine whether a dose dependent response exists.
Light et al4 used oral morphine (08 mg/kg) in patients with severe chronic airflow obstruction and showed that exercise capacity was increased and breathlessness, assessed using a modified Borg scale, significantly decreased. The reduction in breathlessness in this study was achieved at the expense of an increase in arterial carbon dioxide tension, a reduction in ventilatory drive (PO.,), and was thought by the authors to be due to a combination of lowered ventilatory requirements for a given work load and also to altered perception. However, in a subsequent study5 where arterial blood gases remained stable, breathlessness and exercise tolerance were unchanged following the administration of diamorphine. This result suggests that the reduction in breathlessness in Light's earlier study4 is likely to be solely due to changes in ventilatory drive and not specifically to a modification in the perceptive process. Light et al4 used an incremental exercise protocol similar to the one used in our study and that of Masood et all4 and found a beneficial effect from oral morphine, yet no benefit was observed with inhaled morphine by either Masood et al'4 or ourselves. Eiser et al5 used an endurance protocol similar to that of Young et al6 but found no effect from oral morphine and yet Young et al6 found a beneficial effect from inhaled morphine. These results at first seem conflicting except that those studies which found no change in the mechanical and chemical influences on ventilation from their morphine regimen also found no change in the sensation of breathlessness.
Dihydrocodeine administered orally before exercise has also been shown to reduce dyspnoea' by 20% (assessed using a visual analogue scale) in a similar group of patients. Minute ventilation and oxygen consumption were reduced in this study despite an increase in exercise capacity. Similar Other drugs, in particular the benzodiazepines, have been studied for their effect on the relief of breathlessness. Enthusiasm for the therapeutic use of diazepam was engendered by the initial report ofMitchell-Heggs et al7 who reported a "striking" reduction in breathlessness (subjectively assessed) in four men with the "pink puffer syndrome" when treated with this drug. This finding has not been sustained in other studies.8 '16 This syndrome (severe airflow obstruction, relatively preserved gas exchange, and severe breathlessness) probably merges with those subjects considered to have disproportionate breathlessness by Bums and Howell. '7 When this latter group were contrasted with subjects with appropriate breathlessness, there appeared to be increased stress, anxiety, and hyperventilation. It is probable therefore that the action of diazepam in relieving breathlessness in a specific subgroup is related to its anxiolytic properties although it also causes respiratory depression (decreased ventilatory drive) as shown by reductions in carbon dioxide sensitivity. Promethazine was also studied by Woodcock et al and found to reduce breathlessness without altering lung function, but these results were not supported in a subsequent study. '6 Other anxiolytics" 19 and the prostanoid indomethacin2" have been studied with variable results.
The modification ofthe perception ofbreathlessness by pharmacological means in the pursuit of relieving symptoms has received much attention. At the present time the results of these studies have not yielded any specific answers nor provided any clear direction with respect to the specific suppression of the symptom of breathlessness at a central level. Those studies which conclude that breathlessness can be reduced by pharmacological means need to be interpreted with great care because in almost all cases the reduction in breathlessness can be explained in terms of changes in ventilatory drive and/or other aspects of the mechanical or chemical control of breathing. Furthermore, a marked placebo effect has been demonstrated in some patients with airflow obstruction.2' These findings, in addition to the significant incidence of potentially serious side effects, imply that the routine prescription of drugs in pursuit of the relief of breathlessness cannot be recommended at present.
In conclusion, we have shown that the inhalation of morphine sulphate does not relieve exercise induced breathlessness nor does it increase maximum achievable power output during exercise in patients with severe chronic lung disease. Inhaled morphine may theoretically block the peripheral neural receptors in small airways important in mediating the sensation of breathlessness but, if so, then it is ineffective in the doses used in this study.
